Perlecan: An important component of the cartilage pericellular matrix

Journal of Musculoskeletal Neuronal Interactions

Volumn 2, Issue 6, 2002, Pages 511-516

  Gomes, R ^a   Kirn Safran, C ^a   Farach Carson, M C ^a   Carson, D D ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

Cartilage; Extracellular matrix; Heparan sulfate proteoglycan; Mouse; Perlecan

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; GLYCOSAMINOGLYCAN; GROWTH FACTOR; MESSENGER RNA; PERLECAN;

BONE DEVELOPMENT; CARTILAGE CELL; CARTILAGE MATRIX; CELL DIFFERENTIATION; CELL STRAIN; CHONDROGENESIS; DATA ANALYSIS; EXTRACELLULAR MATRIX; GENE MAPPING; GENE MUTATION; GENE STRUCTURE; HUMAN; HYPERTROPHY; IN VITRO STUDY; MATURATION; NONHUMAN; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; STEM CELL; STRUCTURE ANALYSIS; TISSUE ENGINEERING;

EID: 0036979040     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Olsen BR, Reginato AM, Wang W. Bone development. Annu Rev Cell Dev Biol 2000; 16:191-220.
2. Gomes RR, Farach-Carson MC, Carson DD. Perlecan stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro. Connective Tissue Research 2002; (in press).
3. Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D, Beighton P, Hamida CB, Hammouda H, Cruaud C, White PS, Samson D, Urtizberea JA, Lehmann-Horn F, Weissenbach J, Hentati F, Fontaine B. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet 2000; 26:480-483.
4. Chiao E, Fisher P, Crisponi L, Deiana M, Dragatsis I, Schlessinger D, Pilia G, Efstratiadis A. Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Dev Biol 2002; 243:185-206.
5. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet 1999; 23:354-358.
6. Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 1999; 147:1109-1122.
7. Cano-Gauci DF, Song HH, Yang H, McKerlie C, Choo B, Shi W, Pullano R, Piscione TD, Grisaru S, Soon S, Sedlackova L, Tanswell AK, Mak TW, Yeger H, Lockwood GA, Rosenblum ND, Filmus J. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 1999; 146:255-264.
8. Bernard MA, Hogue DA, Cole WG, Sanford T, Snuggs MB, Montufar-Solis D, Duke PJ, Carson DD, Scott A, Van Winkle WB, Hecht JT. Cytoskeletal abnormalities in chondrocytes with EXT1 and EXT2 mutations. J Bone Miner Res 2000; 15:442-450.
9. Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 1998; 273:26265-26268.
10. Park PW, Reizes O, Bernfield M. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem 2000; 275:29923-29926.
11. Pizette S, Niswander L. BMPs are required at two steps of limb chondrogenesis: formation of prechondrogenic condensations and their differentiation into chondrocytes. Dev Biol 2000; 219:237-249.
12. DeLise AM, Fischer L, Tuan RS. Cellular interactions and signaling in cartilage development. Osteoarthritis Cartilage 2000; 8:309-334.
13. Mina M. Morphogenesis of the medial region of the developing mandible is regulated by multiple signaling pathways. Cells Tissues Organs 2001; 169:295-301.
14. SundarRaj N, Fite D, Ledbetter S, Chakravarti S, Hassell JR. Perlecan is a component of cartilage matrix and promotes chondrocyte attachment. J Cell Sci 1995; 108:2663-2672.
15. Handler M, Yurchenco PD, Iozzo RV. Developmental expression of perlecan during murine embryogenesis. Dev Dyn 1997; 210:130-145.
16. French MM, Smith SE, Akanbi K, Sanford T, Hecht J, Farach-Carson MC, Carson DD. Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J Cell Biol 1999; 145:1103-1115.
17. Dodge GR, Kovalszky I, Chu ML, Hassell JR, McBride OW, Yi HF, Iozzo RV. Heparan sulfate proteoglycan of human colon: partial molecular cloning, cellular expression, and mapping of the gene (HSPG2) to the short arm of human chromosome 1. Genomics 1991; 10:673-680.
18. Chakravarti S, Phillips SL, Hassell JR. Assignment of the perlecan (heparan sulfate proteoglycan) gene to mouse chromosome 4. Mamm Genome 1991; 1:270-272.
19. Iozzo RV, Cohen IR, Grassel S, Murdoch AD. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994; 302:625-639.
20. Schulze B, Sasaki T, Costell M, Mann K, Timpl R. Structural and cell-adhesive properties of three recombinant fragments derived from perlecan domain III. Matrix Biol 1996; 15:349-357.
21. Costell M, Sasaki T, Mann K, Yamada Y, Timpl R. Structural characterization of recombinant domain II of the basement membrane proteoglycan perlecan. FEBS Lett 1996; 396:127-131.
22. Brown JC, Sasaki T, Gohring W, Yamada Y, Timpl R. The C-terminal domain V of perlecan promotes betal integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 1997; 250:39-46.
23. Sasaki T, Costell M, Mann K, Timpl R. Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity. FEBS Lett 1998; 435:169-172.
24. Cohen IR, Grassel S, Murdoch AD, Iozzo RV. Structural characterization of the complete human perlecan gene and its promoter. Proc Natl Acad Sci U S A 1993; 90:10404-10408.
25. Iozzo RV, Pillarisetti J, Sharma B, Murdoch AD, Danielson KG, Uitto J, Mauviel A, Structural and functional characterization of the human perlecan gene promoter. Transcriptional activation by transforming growth factor-beta via a nuclear factor 1-binding element. J Biol Chem 1997; 272:5219-5228.
26. Sharma B, Iozzo RV. Transcriptional silencing of perlecan gene expression by interferon-gamma. J Biol Chem 1998; 273:4642-4646.
27. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994; 79:1005-1013.
28. Klein G, Conzelmann S, Beck S, Timpl R, Muller CA. Perlecan in human bone marrow: a growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells. Matrix Biol 1995; 14:457-465.
29. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 1998; 102:1599-1608.
30. Gohring W, Sasaki T, Heldin CH, Timpl R. Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur J Biochern 1998; 255:60-66.
31. Hayashi K, Madri JA, Yurchenco PD. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol 1992; 119:945-959.
32. Battaglia C, Aumailley M, Mann K, Mayer U, Timpl R. Structural basis of beta 1 integrin-mediated cell adhesion to a large heparan sulfate proteoglycan from basement membranes. Eur J Cell Biol 1993; 61:92-99.
33. Durr J, Goodman S, Potocnik A, von der Mark H, von der Mark K. Localization of beta 1-integrins in human cartilage and their role in chondrocyte adhesion to collagen and fibronectin. Exp Cell Res 1993; 207:235-244.
34. Wu JE, Santoro SA. Complex patterns of expression suggest extensive roles for the alpha 2 beta 1 integrin in murine development. Dev Dyn 1994; 199:292-314.
35. Hirsch MS, Svoboda KK. Beta 1 integrin antibodies inhibit chondrocyte terminal differentiation in whole sterna. Ann NY Acad Sci 1996; 785:267-270.
36. Hirsch MS, Lunsford LE, Trinkaus-Randall V, Svoboda KK. Chondrocyte survival and differentiation in situ are integrin mediated. Dev Dyn 1997; 210:249-263.
37. Shakibaei M. Inhibition of chondrogenesis by integrin antibody in vitro. Exp Cell Res 1998; 240:95-106.
38. Kan M, Wang F, To B, Gabriel JL, McKeehan WL. Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex. J Biol Chem 1996; 271:26143-26148.
39. Govindraj P, West L, Koob TJ, Neame P, Doege K, Hassell JR. Isolation and identification of the major heparan sulfate proteoglycans in the developing bovine rib growth plate. J Biol Chem 2002; 277:19461-19469.
40. Arikawa-Hirasawa E, Wilcox WR, Le AH, Silverman N, Govindraj P, Hassell JR, Yamada Y. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet 2001; 27:431-434.
41. Arikawa-Hirasawa E, Le AH, Nishino I, Nonaka I, Ho NC, Francomano CA, Govindraj P, Hassell JR, Devaney JM, Spranger J, Stevenson RE, Iannaccone S, Dalakas MC, Yamada Y. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet 2002; 70:1368-1375.
42. Aberfeld DC, Hinterbuchner LP, Schneider M. Myotonia, dwarfism, diffuse bone disease and unusual ocular and facial abnormalities (a new syndrome). Brain 1965; 88:313-322.
43. San Antonio JD, Winston BM, Tuan RS. Regulation of chondrogenesis by heparan sulfate and structurally related glycosaminoglycans. Dev Biol 1987; 123:17-24.
44. French MM, Gomes RR Jr, Timpl R, Hook M, Czymmek K, Farach-Carson MC, Carson DD. Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I. J Bone Miner Res 2002; 17:48-55.
45. Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM, Rosen V, Wang EA, Tanaka H, Omura S, Suda T. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 1990; 172:295-299.
46. Denker AE, Nicoll SB, Tuan RS. Formation of cartilage-like spheroids by micromass cultures of murine C3H10T1/2 cells upon treatment with transforming growth factor-beta 1. Differentiation 1995; 59:25-34.
47. Atkinson BL, Ryan ME, Benedict JJ, Huffer WE, Gutierrez-Hartmann A. Elucidation of homeoprotein Cart-1 function during in vitro chondrogenesis of C3H10T1/2 micromass cultures. Ann N Y Acad Sci 1996; 785:206-208.
48. Hecht JT, Hall CR, Snuggs M, Hayes E, Haynes R, Cole WG. Heparan sulfate abnormalities in exostosis growth plates. Bone 2002; 31:199-204.